Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 13/20 | 0.34 |
| ▸ | CDK2 | P24941 | 13/20 | 0.34 |
| ▸ | GSK3B | P49841 | 8/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14738613 | 1.00 | EPHX1 (0.38) | EPHX1NAAADPP4CCNE1CDK2 | |
| SCHEMBL7815595 | 0.86 | EPHX1 (0.42) | EPHX1DPP4CCNE1CDK2GSK3B | |
| SCHEMBL27590173 | 0.85 | EPHX1 (0.39) | EPHX1NAAADPP4CCNE1CDK2 | |
| SCHEMBL3693380 | 0.85 | EPHX1 (0.39) | EPHX1NAAADPP4CCNE1CDK2 | |
| Methane SCHEMBL27968861 | 0.84 | EPHX1 (0.41) | EPHX1DPP4CCNE1CDK2GSK3B | |
| SCHEMBL5162097 | 0.83 | PLG (0.39) | EPHX1NAAADPP4CCNE1CDK2 | |
| SCHEMBL28310773 | 0.83 | NAAA (0.40) | EPHX1NAAADPP4CCNE1CDK2 | |
| SCHEMBL5162091 | 0.83 | PLG (0.39) | EPHX1NAAADPP4CCNE1CDK2 | |
| SCHEMBL27593036 | 0.82 | NAAA (0.39) | EPHX1NAAADPP4CCNE1CDK2 | |
| SCHEMBL27891234 | 0.82 | EPHX1 (0.37) | EPHX1NAAADPP4CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107793360-A | Indoleamine 2,3 dioxygenase inhibitors and application | 南京药捷安康生物科技有限公司 | 2018-03-13 | — | — | CN | disclosed |
| US-9744172-B2 | Pyrazolopyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-08-29 | — | — | US | disclosed |
| US-9555030-B2 | Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160279132-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-29 | — | — | US | disclosed |
| US-9290499-B2 | Pyrazolopyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150290212-A1 | THERAPEUTIC USES OF SELECTED PYRAZOLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
| US-20130059836-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279132-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | DPYD, TP53, TYMP | EPHX1 1579/4885NAAA 4533/4885DPP4 888/4885 |
| US-20150290212-A1 | THERAPEUTIC USES OF SELECTED PYRAZOLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | MERTK, TK1, FLT3 | EPHX1 2940/4885NAAA 4326/4885DPP4 1323/4885 |
| US-20130059836-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | DPYD, TYMP, TP53 | EPHX1 1534/4885NAAA 4580/4885DPP4 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.